MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2023
“Updated data show that the combination fostrox + Lenvima® provides improved clinical efficacy compared to Lenvima study data alone in second-line HCC”July – September Financial summary for the quarter · Net turnover amounted to SEK 0.8 (1.1) million. · The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -23.4 (-13.9) million. Basic and diluted earnings per share amounted to SEK -0.42 (-0.27) and SEK -0.42 (-0.27) respectively. · Cash flow from operating activities amounted to SEK -21.0 (-19.7) million. · Cash and cash equivalents at the